Actavis wins US OK for generic Opana ER
This article was originally published in Scrip
Executive Summary
The FDA gave its blessing to Actavis to market a generic version of Endo Pharmaceuticals opioid agonist Opana ER (oxymorphone hydrochloride extended-release), the older version of which was withdrawn from the US market last year.